Skip to main content

Depemokimab FDA Approval Status

Last updated by Judith Stewart, BPharm on March 3, 2025.

FDA Approved: No
Generic name: depemokimab
Company: GlaxoSmithKline
Treatment for: Asthma, Chronic Rhinosinusitis With Nasal Polyps

Depemokimab is a long-acting interleukin-5 antagonist in development for the treatment of asthma with type 2 inflammation and for chronic rhinosinusitis with nasal polyps.

Development timeline for depemokimab

DateArticle
Mar  3, 2025Depemokimab Applications Accepted for Review by the US FDA for Asthma with Type 2 Inflammation and for Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
Mar  1, 2025Depemokimab Delivers Clinically Meaningful and Statistically Significant Improvements for Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
Oct 14, 2024GSK Announces Positive Phase III Results from ANCHOR Trials for Depemokimab in Chronic Rhinosinusitis with Nasal Polyps
May 21, 2024GSK Announces Positive Results from Phase III Severe Asthma Trials of Depemokimab

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.